TICKERNERD
Menu
CNTBCNTBHealthcare · Biotechnology

CNTB Stock Forecast: Connect Biopharma Holdings Ltd. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$0.90
−3.14% on the day

The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. hold a median 12-month price target of $5.5 — +512.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$58.4M
Ticker Nerd rank
31 / 100
Median analyst target
$5.50
Analysts covering
8
Revenue$2.8M+5666.7% y/y
Operating income−$17.6M
Net income−$17.3M
Free cash flow−$15.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.9%
1M
−51.2%
YTD
−68.2%
1Y
−39.7%
From 52W high
−75.7%
From 52W low
0.0%
$0.90
$3.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNTB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Connect Biopharma Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Accruals
79
Revisions
75
Issuance
39
Volatility
30
Value
25
Growth
22
Momentum
13
Quality
8

Size (80): Smaller than most of the companies we track.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26CNTBHigh $9.00Median $5.50Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $4.00Median $5.50High $9.00

The green dot is the last close — the median target sits +512.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
2 Oct 2026HC Wainwright & Co.ReiteratesBuy$7.00
30 Sept 2026BTIGMaintainsBuy$10 → $5.00
22 Sept 2026OppenheimerMaintainsOutperform—
22 Sept 2026OppenheimerMaintainsOutperform$8.00 → $5.00
17 Sept 2026HC Wainwright & Co.ReiteratesBuy—
17 Sept 2026HC Wainwright & Co.ReiteratesBuy$7.00
16 Sept 2026Canaccord GenuityMaintainsBuy—
16 Sept 2026Canaccord GenuityMaintainsBuy$7.00 → $6.00
15 Sept 2026BTIGReiteratesBuy—
15 Sept 2026BTIGReiteratesBuy$10
9 July 2026OppenheimerInitiatesOutperform—
9 July 2026OppenheimerInitiatesOutperform$8.00
26 June 2026Piper SandlerInitiatesOverweight—
25 June 2026HC Wainwright & Co.ReiteratesBuy—
26 May 2026Canaccord GenuityInitiatesBuy—
21 May 2026Cantor FitzgeraldInitiatesOverweight—
1 Apr 2026BTIGReiteratesBuy—
31 Mar 2026BTIGReiteratesBuy—
1 Dec 2025Lake StreetInitiatesBuy—
13 Nov 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNTB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CNTB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Connect Biopharma Holdings Ltd. returned −39.7% against +16.2% for the S&P 500, dividends included.

CNTB vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26CNTBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Connect Biopharma Holdings Ltd. (CNTB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
19.8×

Cheaper than 9% of US stocks

Price / book
2.2×

Cheaper than 42% of US stocks

EV / EBITDA
−0.4×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
5666.7%

Higher than 99% of US stocks

Earnings growth (YoY)
5666.7%

Higher than 99% of US stocks

Gross margin
—
Operating margin
−636.0%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−140.5%

Higher than 10% of US stocks

Return on assets
−69.7%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Connect Biopharma Holdings Ltd. (CNTB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Connect Biopharma Holdings Ltd. has a market value of $58.4M and an enterprise value of $27.5M.

  • Revenue in the twelve months to 30 June 2026: $3.0M. The latest quarter grew 5666.7% year on year.

  • Net income over the same four quarters: −$69.0M, a −2336.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.19.

  • Free cash flow in the twelve months to 30 June 2026: −$60.6M.

  • Shares outstanding: 63.0M.

  • Trailing P/E: −0.9×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Connect Biopharma Holdings Ltd. employs 64 people — $46K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

CNTB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTBConnect Biopharma Holdings Ltd.$58.4M
31
BOLDBoundless Bio, Inc.$58.7M
85
XLOXilio Therapeutics, Inc.$59.2M
74
KLRSKalaris Therapeutics, Inc.$56.6M
18
HYPDHyperion DeFi, Inc.$56.5M
40
INKTMiNK Therapeutics, Inc.$61.8M
61
ACETAdicet Bio, Inc.$62.3M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Connect Biopharma Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNTB news & analysis

Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures

MarketBeat · 4 Oct 2026positive

Connect Biopharma reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients with acute COPD exacerbations. The study met its primary objective, showing an 81% reduction in treatment failures during the month after an exacerbation.

Why it matters — This positive Phase II result for rademikibart advances a key pipeline candidate in Connect Biopharma's COPD development program.

Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

Benzinga · 30 Sept 2026positive

Connect Biopharma Holdings Limited (NASDAQ:CNTB) reported positive topline results from its global Phase 2 study, with its new COPD therapy showing a significant drop in treatment failure. The results were announced recently by the company.

Why it matters — The positive Phase 2 topline results signal promising clinical progress for Connect Biopharma's new COPD therapy, which could be meaningful for the company's development pipeline.

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript

Seeking Alpha · 30 Sept 2026neutral

Connect Biopharma Holdings Limited discussed the topline results of its Seabreeze STAT study, which evaluated rademikibart for chronic obstructive pulmonary disease (COPD) exacerbations, in a transcript covered by Seeking Alpha. The item presents the company's commentary on the study outcomes.

Why it matters — The Seabreeze STAT topline results are a key clinical data point for rademikibart, informing how CNTB watchers assess the program's progress in COPD.

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

GlobeNewsWire · 30 Sept 2026positive

Connect Biopharma announced positive preliminary topline data from its global Phase 2 study of Rademikibart as an add-on treatment for acute exacerbations in adults with COPD and Type 2 inflammation. The treatment significantly reduced the rate of treatment failure compared to placebo by 81% through one month (p=0.0122).

Why it matters — CNTB watchers would care because favorable Phase 2 results for Rademikibart in COPD support the drug's potential and advance its clinical development pipeline.

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript

Seeking Alpha · 16 Sept 2026neutral

Connect Biopharma Holdings Limited discussed topline results from its Phase 2 study of rademikibart for acute asthma exacerbations, as covered in a Seeking Alpha transcript. The company addressed the study's findings in a Q&A format.

Why it matters — The topline results of rademikibart's Phase 2 asthma study are a key development signal for CNTB's lead pipeline candidate and its potential expansion into asthma.

FAQ

Frequently asked questions about CNTB stock

What is the CNTB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. have a median 12-month price target of $5.5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNTB stock a buy right now?

Of the 8 analysts covering Connect Biopharma Holdings Ltd., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Connect Biopharma Holdings Ltd. 31 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNTB?

As at 3 Oct 2026, Connect Biopharma Holdings Ltd. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will CNTB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +512.5% from the last close, and Ticker Nerd's factor model ranks Connect Biopharma Holdings Ltd. 31 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNTB stock forecast for 2030?

No analyst covering Connect Biopharma Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has CNTB stock performed over the past year?

Connect Biopharma Holdings Ltd. returned -39.7% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Connect Biopharma Holdings Ltd. do?

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease.

What is the latest news on CNTB?

The most recent item we track (MarketBeat, 4 Oct 2026): "Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures". Connect Biopharma reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients with acute COPD exacerbations. The study met its primary objective, showing an 81% reduction in treatment failures during the month after an exacerbation.

Company

About Connect Biopharma Holdings Ltd.

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease. Its current pipeline is built around rademikibart, a monoclonal antibody aimed at interleukin-4 receptor alpha, as well as other research efforts in T cell-driven inflammatory disorders. Connect Biopharma works across respiratory and broader inflammation-related markets, reflecting a focus on diseases where immune signaling plays a central role. Headquartered in San Diego, California, Connect Biopharma Holdings Limited is positioned as a specialist developer of novel biologic treatments within the biotechnology sector.

CEO Dr. Barry David Quart Pharm.D. · 64 employees · United States · https://www.connectbiopharm.com